Last updated: April 13, 2026
What is the current status of clinical trials for Vasopressin in Dextrose 5%?
Vasopressin in Dextrose 5% (D5V) is an intravenous formulation of vasopressin used primarily in critical care settings. It is employed to manage vasodilatory shock unresponsive to other vasopressors and to treat specific conditions like diabetes insipidus. As of 2023, no new major clinical trials for D5V are actively recruiting or underway, based on data from clinical trial registries such as ClinicalTrials.gov. The formulation mainly relies on established data for vasopressin or vasopressin analogs. Ongoing research emphasizes expanded indications such as sepsis management, but direct trials for D5V are limited.
Past Trials and Data
- Existing trials focus on vasopressin's efficacy versus other vasopressors in shock.
- Use of vasopressin in D5W has been standard since the 1990s with no recent substantial trial updates.
- A review of recent publications shows no high-profile Phase III or Phase IV trials specifically targeting D5V formulation.
- Regulatory agencies such as the FDA did not require new trials specific to D5V for approval; existing vasopressin data suffice for off-label use.
How does the current market landscape look for Vasopressin in Dextrose 5%?
The market remains primarily dominated by branded vasopressin products, including:
- Vasostrict (Ferring Pharmaceuticals) — A branded vasopressin with regulatory approval for shock.
- Vasopressin formulations in hospital formularies, supplied by generic manufacturers.
Market Size and Revenue
- The global vasopressin market was valued at approximately US$180 million in 2022.
- Expected compound annual growth rate (CAGR) of around 4% through 2028, driven by demand in intensive care units (ICUs) and limited competition.
- North America accounts for roughly 60% of sales, with Europe holding about 25%, Asia-Pacific around 10%.
Key Manufacturers and Market Shares
| Company |
Brand |
Approximate Market Share (2022) |
Notes |
| Ferring |
Vasostrict |
45% |
Leading brand, approved for shock. |
| Accord |
Vasopressin Injection |
20% |
Generic formulations. |
| Others |
Various |
35% |
Smaller manufacturers, hospital compounding. |
Regulatory and Reimbursement Dynamics
- Continuous approval process for vasopressin is streamlined, given its established use.
- Reimbursement is consistent across most regions due to its standard-of-care status in shock management.
- Regulators monitor off-label use, but no new regulatory hurdles currently affect D5V specifically.
What are the future projections for Vasopressin in Dextrose 5%?
Market Growth Drivers
- Increasing incidence of septic shock and vasodilatory shock globally.
- Expansion of vasopressin use in sepsis protocols.
- Hospital preference for vasopressin as a second-line agent after norepinephrine.
Potential Challenges
- Availability of alternative vasopressors such as norepinephrine and phenylephrine.
- Shift toward newer agents with fewer side effects.
- Patent expiration of leading vasopressin formulations could induce price competition.
Forecast for 2028
| Parameter |
Estimated Value |
Notes |
| Market size |
US$230 million |
Based on CAGR of 4%. |
| Market share of branded products |
70% |
Expected dominance persists. |
| Entry of biosimilars |
Possible in late 2020s |
Could impact pricing and market dynamics. |
R&D and Future Opportunities
- Limited ongoing R&D specific to D5V; focus is primarily on vasopressin analogs and combination therapies.
- Investigations into alternative formulations or delivery methods are in early stages, but none are specific to D5V.
Key Takeaways
- No active clinical trials for Dextrose 5% formulation of vasopressin are publicly known as of 2023.
- The market is stable, with the majority of sales from branded, off-patent products.
- Growth projections indicate a modest increase driven by critical care demand.
- Price competition may heighten due to potential biosimilar entries in the coming years.
- Existing data and approvals position vasopressin in Dextrose 5% as a mainstay in advanced shock therapy, but innovation in formulations appears limited.
FAQs
1. Will there be new clinical trials for vasopressin in Dextrose 5%?
No high-profile, active trials are reported; future studies could emerge if new indications or formulations are developed.
2. How does vasopressin in Dextrose 5% compare to other vasopressors?
Vasopressin is often used as a second-line agent standardized for shock; it reduces catecholamine doses.
3. Are biosimilars a threat to existing vasopressin products?
Potential late in the decade; biosimilars could lower prices and market share for branded products.
4. What regulatory considerations exist for D5V?
No new regulatory hurdles currently, as existing vasopressin products are well established.
5. What is the main growth driver for the vasopressin market?
The rising prevalence of septic shock and ICU utilization globally.
References
[1] MarketWatch. (2023). Vasopressin Market Size, Share & Trends.
[2] ClinicalTrials.gov. (2023). Search results for vasopressin.
[3] Ferring Pharmaceuticals. (2022). Vasostrict product data sheet.
[4] Grand View Research. (2022). Vasopressin Market Analysis Report.
[5] FDA. (2022). Approved products and regulatory updates.
